Melanoma cell lines belonging to distinct mutational groups (BRAF-mutant, NRAS-mutant, or wild type for both BRAF and NRAS, Supplementary Fig. S19a top and bottom panels) co-expressed NFATc2 and EZH2 supporting the rationale for testing the potential anti-tumor effects of pharmacological co-targeting. Here, NFATC2 is linked to neoplasm.